New molecular entity: FDA approved teriflunomide (Aubagio, Genzyme, a Sanofi-Aventis company), a pyrimidine synthesis inhibitor, for the treatment of patients with relapsing forms of multiple sclerosis (MS).

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Aubagio (Teriflunomide)

Newsletter